Trials / Completed
CompletedNCT05550636
A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood
The Effect of Multiple Oral Doses of BI 1015550 on Metabolism of Midazolam Administered Orally in Healthy Male Subjects (Open-label, Two-period Fixed Sequence Design Trial)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this trial is to investigate the induction effect of multiple doses of BI 1015550 on the pharmacokinetics of the sensitive CYP3A4 substrate midazolam.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1015550 | BI 1015550 |
| DRUG | midazolam | midazolam |
Timeline
- Start date
- 2022-10-11
- Primary completion
- 2022-12-19
- Completion
- 2022-12-19
- First posted
- 2022-09-22
- Last updated
- 2025-12-01
- Results posted
- 2025-12-01
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05550636. Inclusion in this directory is not an endorsement.